Please login to the form below

Not currently logged in
Email:
Password:

biologic

This page shows the latest biologic news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

as eczema) - a chronic skin condition characterised by skin blistering, cracking and often debilitating itching - and is the first targeted biologic drug for this purpose.

Latest news

More from news
Approximately 17 fully matching, plus 545 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Jill Ogden has over 30 years of commercial and R&D experience in the biopharmaceuticals and healthcare industries and provides our biologics, early stage deals and platform technologies expertise.

  • The good, the bad and the ugly The good, the bad and the ugly

    Humira is entrenched as a first-line biologic for the treatment of numerous conditions - and despite the EU launch of biosimilars in 2018, we anticipate that it will remain a ... Its revenues grew by a further 9% last year. “A large percentage of this

  • The tipping point The tipping point

    Biologics represent a significant proportion of these innovative medicines and a substantial portion of the global drugs budget. ... In 2016 biologics accounted for 17% of global medicines spend - that’s about 175bn.

  • Biologic or biosimilar: what are prescribers thinking? Biologic or biosimilar: what are prescribers thinking?

    Biologic or biosimilar: what are prescribers thinking? Biosimilars are raising their competitive game, but are physicians convinced? ... And how do these factors affect the ultimate choice of a biologic vs biosimilar?

  • Pushing the accelerator Pushing the accelerator

    What is the limiting factor? While software can’t speed up the research to develop the molecule or biologic, it can have a significant impact on speeding up the process.

More from intelligence
Approximately 2 fully matching, plus 62 partially matching documents found.

Latest appointments

More from appointments
Approximately 7 fully matching, plus 43 partially matching documents found.

Latest from PMHub

  • Introduction to the manufacturing of biologics

    What is a biologic? Before looking at how to manufacture them, it’ s important to first understand what a biologic is. ... Biologics differ from small molecule drugs in their cost, production, administration, and clinical efficacy.

  • Tackling biosimilars – how to handle the threat to Pharma brands

    The crux of the challenge lies in the creation and availability of ‘ biosimilars’; biologic drugs which are copies of the previously patented, original biologic drugs. ... But how similar can they be? Biologic drugs are incredibly complex to make,

  • Biosimilars - the Brexit of the pharmaceutical industry?

    of the  British Generic Manufacturers Association (BGMA).Biosimilars are undoubtedly a hot topic for providers of branded biologic medicines, biosimilar suppliers themselves, and the payers, healthcare professionals and patients involved in

  • How can pharma engage with the top performing STPs?

    there. This incentive has encouraged a number of pharma companies to work with the NHS to set up medication delivery services, particularly for injectables and some of the biologics, enabling them

  • The Biosimilar Challenge

    This makes for an interesting dynamic in the industry where companies are rigorously defending their own branded biologic patents whilst simultaneously developing biosimilar versions of competitors to take into the market.

More from PMHub
Approximately 6 fully matching, plus 33 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics